{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.6","upperLimit":"47.4","value":"41.4"},{"groupId":"OG001","lowerLimit":"16.3","upperLimit":"30.9","value":"23.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"280"},{"groupId":"OG001","value":"139"}],"units":"Participants"}],"description":"Defined as achieving a best overall response of confirmed CR or confirmed PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"NUMBER","populationDescription":"ITT - PFS population, subset of participants with measurable disease by investigator at baseline. The ITT-PFS Population includes the first 480 randomized participants in the ITT analysis population (evaluated by their randomized treatment assignment).","reportingStatus":"POSTED","timeFrame":"34.6 months","title":"ORR Per RECIST 1.1 as Determined by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}